1 / 6

Candidiasis Therapeutics Pipeline Analysis Clinical Trials & Results

The study analyzed that the candidiasis therapeutics pipeline comprises approximately 22 drug candidates in different stages of development.<br><br>As per the findings of the research, most of the candidiasis drug candidates are being developed to be administered by oral route.<br><br>Matinas Biopharma Holdings, Inc. is using Cochleate technology platform for the development of their drug candidates. The technology platform is a lipid-crystal nano-particle targeted drug delivery system, that offers a drug delivery solution with differentiating and disruptive features including oral availability, multi-organ protection, enhanced safety and targeted delivery to the site of the infection and inflammation along with the ability to effectively penetrate the tissues.

NidhiNehani
Download Presentation

Candidiasis Therapeutics Pipeline Analysis Clinical Trials & Results

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Candidiasis Therapeutics Pipeline to Witness Many Technological Advancements in the Coming Years

  2. Candidiasis Therapeutics According to a new research report “Candidiasis Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Market Research, Candidiasis currently exhibits a pipeline with 22 drug candidates. Explore Report Description at: https://www.psmarketresearch.com/market-analysis/candidiasis-therapeutics-pipeline-analysis Candidiasis therapeutics pipeline in 2017 The study analyzed that the candidiasis therapeutics pipeline comprises approximately 22 drug candidates in different stages of development.

  3. Candidiasis Therapeutics Insights on pipeline segments As per the findings of the research, most of the candidiasis drug candidates are being developed to be administered by oral route. Cochleate technology platform for Candidiasis drug development Matinas Biopharma Holdings, Inc. is using Cochleate technology platform for the development of their drug candidates. The technology platform is a lipid-crystal nano-particle targeted drug delivery system, that offers a drug delivery solution with differentiating and disruptive features including oral availability, multi-organ protection, enhanced safety and targeted delivery to the site of the infection and inflammation along with the ability to effectively penetrate the tissues.

  4. Candidiasis Therapeutics Ample Designations from the U.S. Food and Drug Administration (USFDA) to the market players manufacturing drugs for Candidiasis The research found that various companies received many designations from the U.S. Food and Drug Administration (USFDA) for the development of candidiasis therapeutics pipeline. In May 2016, USFDA granted the orphan drug designation to SCY-078 for the treatment of invasive candida infections, including candidemia. Some of the key players developing drugs for the treatment of candidiasis include Seren Pharmaceuticals, Inc., SCYNEXIS, Inc., Matinas Biopharma Holdings, Inc., and others.

  5. Candidiasis Therapeutics Download report sample at: https://www.psmarketresearch.com/market-analysis/candidiasis-therapeutics-pipeline-analysis/report-sample

  6. GET IN TOUCH THANK YOU! For information regarding permissions and other queries Kindly write to: US/Canada Toll-Free: 1-888-778-7886

More Related